CC-98633 is a BCMA targeted Chimeric Antigen Receptor (CAR) T Cell therapy that is being evaluated in multiple myeloma.
|Developed By||Juno Therapeutics, a Subsidiary of Celgene|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.